KIT as a therapeutic target for non-oncological diseases

Martínez-Antón, Asunción; Gras, Delphine; Bourdin, Arnaud; Dubreuil, Patrice; Chanez, Pascal

doi:10.1016/j.pharmthera.2018.12.008

Cited by 17 publications

(14 citation statements)

References 501 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The molecular mechanism indicates that there is a large amount of crossover and overlap among the downstream signaling pathways of RTKs. For example, SRC kinase, which plays a key role in the development of osteosarcoma ( 153 ), can be activated, respectively by VEGFRs ( 154 ), KIT ( 81 ), RET ( 90 ), PDGFRs ( 103 ), IGF-1R ( 155 ), and AXL ( 148 ). Therefore, it can be determined that inhibition of one type of RTKs is not effective in the treatment of osteosarcoma.…”

Section: Discussionmentioning

confidence: 99%

“…The KIT is a kind of RTK, and its ligand is stem cell factor ( 81 ). KIT also contains an extracellular domain, a transmembrane domain, and an intracellular domain ( 82 ).…”

Section: Which Rtk Is the Key Target?mentioning

confidence: 99%

“…After binding with a ligand, KIT induces multiple signaling cascades, which are essential for biological processes including cell differentiation, proliferation, and migration ( 83 ). KIT plays important roles in the functioning of nervous system, kidney, gastrointestinal tract, bones, lungs, and pancreas ( 81 ). Abnormal expression of KIT has been documented in various neoplasms ( 82 , 84 ).…”

Section: Which Rtk Is the Key Target?mentioning

confidence: 99%

See 2 more Smart Citations

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

2020

View full text Add to dashboard Cite

Recent clinical trials have shown several multi-target tyrosine kinase inhibitors (TKIs) to be effective in the treatment of osteosarcoma. However, these TKIs have a number of targets, and it is yet unclear which of these targets has a key role in osteosarcoma treatment. In this review, we first summarize the TKIs that were studied in clinical trials registered on ClinicalTrials.gov. Further, we compare and discuss the targets of these TKIs. We found that TKIs with promising therapeutic effect for osteosarcoma include apatinib, cabozantinib, lenvatinib, regorafenib, and sorafenib. The key targets for osteosarcoma treatment may include VEGFRs and RET. The receptor tyrosine kinases (RTKs) MET, IGF-1R, AXL, PDGFRs, KIT, and FGFRs might be relevant but unimportant targets for osteosarcoma treatment. Inhibition of one type of RTK for the treatment of osteosarcoma is not effective. It is necessary to inhibit several relevant RTKs simultaneously to achieve a breakthrough in osteosarcoma treatment. This review provides comprehensive information on TKI targets relevant in osteosarcoma treatment, and it will be useful for further research in this field.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The KIT is a kind of RTK, and its ligand is stem cell factor ( 81 ). KIT also contains an extracellular domain, a transmembrane domain, and an intracellular domain ( 82 ).…”

Section: Which Rtk Is the Key Target?mentioning

confidence: 99%

Section: Which Rtk Is the Key Target?mentioning

confidence: 99%

See 1 more Smart Citation

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

2020

View full text Add to dashboard Cite

show abstract

“…SCF-KIT signaling pathway. Recent studies have verified the important roles of the SCF-KIT signaling pathway in melanocyte proliferation and differentiation, and the process of melanogenesis (29,30). SCF is a paracrine factor that is secreted by fibroblasts, whereas c-KIT, its receptor, is expressed on melanocytes (31).…”

Section: Core Signaling Pathways In the Regulation Of Melanogenesismentioning

confidence: 94%

Natural skin‑whitening compounds for the treatment of melanogenesis (Review)

et al. 2020

View full text Add to dashboard Cite

Melanogenesis is the process for the production of melanin, which is the primary cause of human skin pigmentation. Skin-whitening agents are commercially available for those who wish to have a lighter skin complexions. To date, although numerous natural compounds have been proposed to alleviate hyperpigmentation, insufficient attention has been focused on potential natural skin-whitening agents and their mechanism of action from the perspective of compound classification. In the present article, the synthetic process of melanogenesis and associated core signaling pathways are summarized. An overview of the list of natural skin-lightening agents, along with their compound classifications, is also presented, where their efficacy based on their respective mechanisms of action on melanogenesis is discussed.

show abstract

“…The KIT ligand, KITL, also called stem cell factor (SCF), is a receptor protein tyrosine kinase (Martinez-Anton et al, 2019). KITL plays important roles in primordial follicle activation, oocyte growth and survival, and granulosa cell proliferation in mammals (Tan et al, 2017;Adib et al, 2019;Islam et al, 2020).…”

Section: Kitl-kit Signaling Is the Bridge Between Pfgcs And The Dormamentioning

confidence: 99%

The Factors and Pathways Regulating the Activation of Mammalian Primordial Follicles in vivo

Yao

Yang

Shi

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Mammalian ovaries consist of follicles as basic functional units. Each follicle comprised an innermost oocyte and several surrounding flattened granulosa cells. Unlike males, according to the initial size of the primordial follicle pool and the rate of its activation and depletion, a female's reproductive life has been determined early in life. Primordial follicles, once activated, will get into an irreversible process of development. Most follicles undergo atretic degeneration, and only a few of them could mature and ovulate. Although there are a lot of researches contributing to exploring the activation of primordial follicles, little is known about its underlying mechanisms. Thus, in this review, we collected the latest papers and summarized the signaling pathways as well as some factors involved in the activation of primordial follicles, hoping to lead to a more profound understanding of the cellular and molecular mechanisms of primordial follicle activation.

show abstract

KIT as a therapeutic target for non-oncological diseases

Cited by 17 publications

References 501 publications

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

Natural skin‑whitening compounds for the treatment of melanogenesis (Review)

The Factors and Pathways Regulating the Activation of Mammalian Primordial Follicles in vivo

Contact Info

Product

Resources

About